Skip to main content

Flagship Pioneering — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

70
Companies
$4.9B
Total invested
$73.8M
Avg. check
26
Industries
Biotechnology 19Health Care 10Medical 8Therapeutics 8Artificial Intelligence (AI) 5Life Science 5+20 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 70
Montai Therapeutics
December 2022

Montai Health platform enables rapid and repeatable advancement of therapies across multiple diseases.

Health Care · Cambridge$50.0M Series A
Harbinger Health
January 2025

Harbinger Health is a biotechnology company that develops a two-tier testing model for the detection of early cancer with a blood test.

Artificial Intelligence (AI) · Cambridge$100.0M Venture - Series Unknown
CIBO
January 2024

CIBO scales regenerative advanced platform technology that connects growers to incentives and enterprises to growers.

Agriculture · Saint Louis ParkSeries C
Cellarity
October 2022

Cellarity is a therapeutics company that uses genomic technologies, data science, and AI to develop a new generation of therapies.

Biotechnology · Somerville$121.0M Series C
Seres Therapeutics
October 2025

Seres Therapeutics is a microbiome therapeutics company that develops treatments for serious diseases.

Biopharma · Cambridge$3.6M Grant
Valo Health
October 2022

Valo Health is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics.

Biotechnology · BostonSeries C
Expedition Medicines
October 2025

Expedition Medicines develops an AI-powered platform that creates small-molecule drugs for previously inaccessible disease targets.

Artificial Intelligence (AI) · Cambridge$50.0M Series A
Axcella
October 2022

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

Biotechnology · Cambridge$34.2M Post-IPO Equity
Invaio Sciences
October 2021

Invaio Sciences is a technology company that is dedicated to solving pressing agriculture, nutrition, and environmental challenges.

Agriculture · Cambridge$50.0M Debt Financing
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post Ipo Equity
Denali Therapeutics
December 2025

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Biotechnology · San Francisco$200.0M Post Ipo Debt
Extuitive
September 2025

Extuitive is an AI-first business that aims to revolutionize the conception and validation of new consumer goods and creatives.

Artificial Intelligence (AI) · Cambridge$20.0M Seed
Terrana Biosciences
July 2025

Terrana's innovative technology platform uses RNA-based plant health solutions to enable resilient agriculture for a world.

Agriculture · Cambridge$50.0M Series B
Etiome
April 2025

Etiome, a company redefining how we detect and preempt disease progression.

Biotechnology · Cambridge$50.0M Series A
Ampersand Biomedicines
March 2025

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

Biopharma · Boston$65.0M Series B
Indigo
March 2025

Indigo is an agricultural technology company that focuses on improving sustainability and profitability in farming practices.

Agriculture · Boston$1.5M Series Unknown
Mirai Bio
September 2024

Mirai Bio provides access to end-to-end development capabilities with innovation at every step.

Artificial Intelligence (AI) · Cambridge$50.0M Series A
Apriori Bio
July 2024

Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.

Biotechnology · Boston$1.1M Grant
Prologue Medicines
May 2024

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Health Care · Cambridge$50.0M Series A
Quotient Therapeutics
November 2023

Quotient Therapeutics engages in transformative medicines made possible with somatic genomics.

Biotechnology · London$50.0M Seed
Alltrna
August 2023

Alltrna is the creator of a tRNA platform that aims to decipher tRNA biology and pioneer therapies for disease treatment.

Biotechnology · Cambridge$109.0M Series B
Evelo Biosciences
July 2023

Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.

Biotechnology · Cambridge$25.5M Post Ipo Equity
Empress Therapeutics
June 2023

Empress Therapeutics is to generate transformative drug candidates that get to the clinic faster and cheaper.

Artificial Intelligence (AI) · Cambridge$50.0M Series Unknown
Metaphore Biotechnologies
May 2023

Metaphore Biotechnologies is a firm that uses biomimicry and machine learning to unlock the revolutionary therapeutic.

Biotechnology · Cambridge$50.0M Undisclosed

Where Flagship Pioneering invests

Biotechnology19
Health Care10
Medical8
Therapeutics8
Artificial Intelligence (AI)5
Life Science5

About Flagship Pioneering's portfolio

How many companies has Flagship Pioneering invested in?

Flagship Pioneering has invested in 70 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Flagship Pioneering invest in?

Flagship Pioneering's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Artificial Intelligence (AI). The firm invests across 26 different industry categories.

What is Flagship Pioneering's largest investment?

Among tracked funding rounds, Denali Therapeutics received $200.0M in a Post Ipo Debt round. Flagship Pioneering's total known invested capital is $4.9B.

What is the average investment size for Flagship Pioneering?

Flagship Pioneering's average investment size is $73.8M across its portfolio of 70 companies.

What are Flagship Pioneering's most recent investments?

Recent Flagship Pioneering portfolio additions include Montai Therapeutics, Harbinger Health, CIBO, Cellarity, Seres Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 70 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →